GSK, Merck, AstraZeneca Sue Sun Over Zejula Cancer Drug Copies

Sun Pharmaceutical Industries Ltd.’s proposed copies of the cancer drug Zejula infringe four patents owned or exclusively licensed by units of GSK Plc, Merck & Co., and AstraZeneca Plc, two federal lawsuits said.

Sun’s proposed generic tablets of 100-, 200-, and 300-milligram dosages of niraparib, Zejula’s active ingredient, infringe US Patent Nos. 8,071,623, 11,091,459, 11,673,877, and 8,859,562, according to complaints docketed Sept. 19 in New Jersey and Delaware district courts. Zejula is used to treat ovarian and related gynecologic cancers.

The Delaware complaint alleges infringement of the ‘623 patent, which Merck Sharp & ...